Arecor Therapeutics chief executive Sarah Howell talks to Proactive about a new, exclusive collaboration with a top-five global pharmaceutical company (which remains un-named).
Howell explains that Arecor will use its formulation technology platform, called Arestat, to develop high-concentration liquid formulations of the pharma group's proprietary products.
Arecor's partner will fund the initial development work and will have the option to acquire the rights to the new proprietary formulations and associated intellectual property under a technology licensing model.